Evaluating the feasibility and acceptability of expectation-optimized open-label placebo as an adjuvant treatment for chronic pain - chronic pain is prevalent and is a major clinical, social, and…

Active Grant Awarded

Award ID
R34AT013235
Recipient
Awarding agency
Obligated
$692,332

Award facts

Completion date 7% complete
Place of performance
Baltimore, MD 21201, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Center for Complementary and Integrative Health awarded University of Maryland, Baltimore $692,332 on September 9, 2026, under grant R34AT013235 and Assistance Listing 93.213, Research and Training in Complementary and Integrative Health. The award funds a feasibility and acceptability study of expectation-optimized open-label placebo (OLP) as an adjuvant treatment for chronic pain. The project adapts OLP with a procedure that targets patient expectations, in a cohort of participants with chronic orofacial pain. The source states that OLP efficacy in randomized trials has ranged from small to medium, which has prevented its reliable use as an adjuvant chronic pain treatment, and that positive treatment expectations are critical to OLP analgesic effects.

The dollars obligated total $692,332. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2029. Work is performed in Baltimore, Maryland 21201.

The program funds research into complementary and integrative health approaches, and eligible applicants include research and academic institutions. The source does not identify sub-recipients for this award.

Description

Evaluating the feasibility and acceptability of expectation-optimized open-label placebo as an adjuvant treatment for chronic pain - chronic pain is prevalent and is a major clinical, social, and economic problem. The incidence rate of chronic pain increased to 46% based on a national survey in the US that was conducted in 2020. The direct cost to the healthcare system is estimated to be high as $261 to 300 billion. Despite the high prevalence and high cost, an optimal treatment is not yet found to cure or manage chronic pain. Traditional pharmacological treatments for chronic pain such as the use of non-steroidal anti-inflammatory drugs (NSAIDS) has been shown to have moderate effect sizes and medications such as opioids have suffered from easily developed high drug tolerance, side effects, and potential problems of addiction. Therefore, the NIH has proposed non-pharmacological treatment as the first option for chronic pain treatment. This project aims to adapt a promising adjuvant treatment open-label placebo (OLP) with optimizing expectation management in a cohort of chronic orofacial pain. OLP are placebos that are given transparently without deception. We and others have shown certain efficacy of OLP in mitigating chronic pain in participants with chronic temporomandibular disorders, lower back pain, and osteoarthritis. However, the effect size of the OLP efficacy in randomized clinical trials has been heterogenous, ranging from small to medium, preventing its reliable and robust use as an adjuvant treatment for chronic pain. Notably, empirical evidence has shown that positive treatment expectations are critical in driving the OLP induced analgesic effects. However, the current OLP instruction lack a procedure specifically targets expectations. Moreover, the negative lay perception about OLP prevent IT from being actively included in participants' daily medication regimen. Recently, a novel expectation optimization psychotherapy expect has been developed to boost the expectations in patients undergoing cardiac surgeries and has shown to be efficacious in improving post-surgical pain disability and reducing side effects. This R34 proposes to adapt the original expect therapy to shape the expectations towards OLP (OLP-EXP) and general chronic pain management (EXP only). We will follow the adapt guidelines to OLP-EXP and EXP only. In aim 1, we will adapt the expect content to meet the needs of chronic pain participants, while maintaining the key features of the original expect. Aim 2 will be a feasibility randomized control trial to collect information on retention rate, and adherence rate to OLP-EXP and EXP only in comparison with OLP only. A semi-structured interview will be conducted at the end to understand participants' attitudes towards the OLP- EXP, EXP only, and OLP only interventions. Overall, assessing feasibility and acceptability of the OLP-EXP and EXP only provide guidance for preparing subsequent larger scale rigorous efficacy and effectiveness studies. After the completion of this trial, we aim to conduct a subsequent clinical efficacy trial under the nccih's mission.

Quick answers

Who received award R34AT013235?

R34AT013235 was awarded to University Of Maryland, Baltimore by National Center for Complementary and Integrative Health (National Institutes of Health) on September 9, 2026.

How much is award R34AT013235 worth?

$692,332 has been obligated on R34AT013235.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award